A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Trial Profile

A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Vemurafenib (Primary) ; Tizanidine
  • Indications Malignant melanoma; Muscle spasticity
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 05 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
    • 07 Oct 2013 Planned end date changed from 1 Jul 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top